{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-026130","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.887216+00:00","generated_at":"2026-05-24T10:09:16.399134+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Verastem updates pipeline; PDUFA June 30, 2025 for avutometinib+defactinib in LGSOC","bullets":["PDUFA action date June 30, 2025 for NDA of avutometinib+defactinib in KRAS mutant recurrent LGSOC; launch prep underway.","RAMP 201 data: 44% ORR in KRAS mt, 31% overall; median PFS 12.9 months; 82% of patients had tumor shrinkage.","Confirmatory RAMP 301 Phase 3 enrollment on track for completion by end of 2025.","Filed U.S. IND for VS-7375 (KRAS G12D inhibitor) in Q1 2025; Phase 1/2a initiation expected mid-2025.","Plan to present RAMP 203 (NSCLC) and RAMP 205 (pancreatic) data at med meetings in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-026130","json":"https://secwatch.observer/filing/0001104659-25-026130.json","markdown":"https://secwatch.observer/filing/0001104659-25-026130.md","text":"https://secwatch.observer/filing/0001104659-25-026130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925026130/0001104659-25-026130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925026130/tm259913d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:09:16.399134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}